179 related articles for article (PubMed ID: 37667319)
1. Baroreflex activation therapy in patients with heart failure with reduced ejection fraction: a single-centre experience.
Blanco C; Madej T; Mangner N; Hommel J; Grimm S; Knaut M; Linke A; Winzer EB
ESC Heart Fail; 2023 Dec; 10(6):3373-3384. PubMed ID: 37667319
[TBL] [Abstract][Full Text] [Related]
2. Baroreflex Activation Therapy in Patients With Heart Failure With Reduced Ejection Fraction.
Zile MR; Lindenfeld J; Weaver FA; Zannad F; Galle E; Rogers T; Abraham WT
J Am Coll Cardiol; 2020 Jul; 76(1):1-13. PubMed ID: 32616150
[TBL] [Abstract][Full Text] [Related]
3. Baroreflex activation therapy with the Barostim™ device in patients with heart failure with reduced ejection fraction: a patient level meta-analysis of randomized controlled trials.
Coats AJS; Abraham WT; Zile MR; Lindenfeld JA; Weaver FA; Fudim M; Bauersachs J; Duval S; Galle E; Zannad F
Eur J Heart Fail; 2022 Sep; 24(9):1665-1673. PubMed ID: 35713888
[TBL] [Abstract][Full Text] [Related]
4. Baroreflex activation therapy in patients with heart failure and a reduced ejection fraction: Long-term outcomes.
Zile MR; Lindenfeld J; Weaver FA; Zannad F; Galle E; Rogers T; Abraham WT
Eur J Heart Fail; 2024 Apr; 26(4):1051-1061. PubMed ID: 38606555
[TBL] [Abstract][Full Text] [Related]
5. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy.
Zile MR; Abraham WT; Weaver FA; Butter C; Ducharme A; Halbach M; Klug D; Lovett EG; Müller-Ehmsen J; Schafer JE; Senni M; Swarup V; Wachter R; Little WC
Eur J Heart Fail; 2015 Oct; 17(10):1066-74. PubMed ID: 26011593
[TBL] [Abstract][Full Text] [Related]
6. Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction.
Abraham WT; Zile MR; Weaver FA; Butter C; Ducharme A; Halbach M; Klug D; Lovett EG; Müller-Ehmsen J; Schafer JE; Senni M; Swarup V; Wachter R; Little WC
JACC Heart Fail; 2015 Jun; 3(6):487-496. PubMed ID: 25982108
[TBL] [Abstract][Full Text] [Related]
7. Baroreflex activation therapy for the treatment of heart failure with reduced ejection fraction in patients with and without coronary artery disease.
Halbach M; Abraham WT; Butter C; Ducharme A; Klug D; Little WC; Reuter H; Schafer JE; Senni M; Swarup V; Wachter R; Weaver FA; Wilks SJ; Zile MR; Müller-Ehmsen J
Int J Cardiol; 2018 Sep; 266():187-192. PubMed ID: 29705650
[TBL] [Abstract][Full Text] [Related]
8. Baroreflex Activation Therapy in Patients with Heart Failure with a Reduced Ejection Fraction.
Ruddy JM; Kroman A; Baicu CF; Zile MR
Heart Fail Clin; 2024 Jan; 20(1):39-50. PubMed ID: 37953020
[TBL] [Abstract][Full Text] [Related]
9. Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection Fraction.
Weaver FA; Abraham WT; Little WC; Butter C; Ducharme A; Halbach M; Klug D; Lovett EG; Madershahian N; Müller-Ehmsen J; Schafer JE; Senni M; Swarup V; Wachter R; Zile MR
Semin Thorac Cardiovasc Surg; 2016 Summer; 28(2):320-328. PubMed ID: 28043438
[TBL] [Abstract][Full Text] [Related]
10. Restoration of normal sympathetic neural function in heart failure following baroreflex activation therapy: final 43-month study report.
Dell'Oro R; Gronda E; Seravalle G; Costantino G; Alberti L; Baronio B; Staine T; Vanoli E; Mancia G; Grassi G
J Hypertens; 2017 Dec; 35(12):2532-2536. PubMed ID: 28816745
[TBL] [Abstract][Full Text] [Related]
11. Baroreflex activation therapy in advanced heart failure therapy: insights from a real-world scenario.
Guckel D; Eitz T; El Hamriti M; Braun M; Khalaph M; Imnadze G; Fink T; Sciacca V; Sohns C; Sommer P; Nölker G
ESC Heart Fail; 2023 Feb; 10(1):284-294. PubMed ID: 36208130
[TBL] [Abstract][Full Text] [Related]
12. Response by Sex in Patient-Centered Outcomes With Baroreflex Activation Therapy in Systolic Heart Failure.
Lindenfeld J; Gupta R; Grazette L; Ruddy JM; Tsao L; Galle E; Rogers T; Sears S; Zannad F
JACC Heart Fail; 2021 Jun; 9(6):430-438. PubMed ID: 33992562
[TBL] [Abstract][Full Text] [Related]
13. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760
[TBL] [Abstract][Full Text] [Related]
14. Long-term chronic baroreflex activation: persistent efficacy in patients with heart failure and reduced ejection fraction.
Gronda E; Seravalle G; Trevano FQ; Costantino G; Casini A; Alsheraei A; Lovett EG; Vanoli E; Mancia G; Grassi G
J Hypertens; 2015 Aug; 33(8):1704-8. PubMed ID: 26132760
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial.
Butt JH; Adamson C; Docherty KF; de Boer RA; Petrie MC; Inzucchi SE; Kosiborod MN; Maria Langkilde A; Lindholm D; Martinez FA; Bengtsson O; Schou M; O'Meara E; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Jhund PS; McMurray JJV; Køber L
Circ Heart Fail; 2021 Dec; 14(12):e008837. PubMed ID: 34802253
[TBL] [Abstract][Full Text] [Related]
16. Non-pharmacologic autonomic neuromodulation for treatment of heart failure: A systematic review and meta-analysis of randomized controlled trials.
Ahmed M; Nudy M; Bussa R; Weigel F; Naccarelli G; Maheshwari A
Trends Cardiovasc Med; 2024 Feb; 34(2):101-107. PubMed ID: 36202286
[TBL] [Abstract][Full Text] [Related]
17. An early analysis of cost-utility of baroreflex activation therapy in advanced chronic heart failure in Germany.
Borisenko O; Müller-Ehmsen J; Lindenfeld J; Rafflenbeul E; Hamm C
BMC Cardiovasc Disord; 2018 Aug; 18(1):163. PubMed ID: 30092774
[TBL] [Abstract][Full Text] [Related]
18. [Baroreflex activation therapy. A novel interventional approach to treat heart failure with reduced ejection fraction].
Halbach M; Fritz T; Madershahian N; Pfister R; Reuter H
Herz; 2015 Nov; 40(7):959-65. PubMed ID: 26525523
[TBL] [Abstract][Full Text] [Related]
19. The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings.
Mazza A; Townsend DM; Torin G; Schiavon L; Camerotto A; Rigatelli G; Cuppini S; Minuz P; Rubello D
Biomed Pharmacother; 2020 Oct; 130():110596. PubMed ID: 34321170
[TBL] [Abstract][Full Text] [Related]
20. Effects of chronic carotid baroreceptor activation on arterial stiffness in severe heart failure.
Gronda E; Brambilla G; Seravalle G; Maloberti A; Cairo M; Costantino G; Lovett E; Vanoli E; Mancia G; Grassi G
Clin Res Cardiol; 2016 Oct; 105(10):838-46. PubMed ID: 27120329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
